Vivani Medical, Inc. is a biotechnology company focused on developing innovative drug delivery solutions to improve patient outcomes in chronic disease management
The company's primary expertise lies in the creation of miniaturized implantable devices that provide sustained release of therapeutic agents over extended periods. By enhancing the delivery of medications for conditions such as diabetes and obesity, Vivani aims to offer safer, more effective alternatives to traditional treatment methods, thereby transforming the way patients manage their health. The commitment to advancing medical technology drives Vivani's research and development endeavors, with a vision to make a meaningful impact on healthcare.
Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative biopharmaceutical company developing novel, ultra long-acting drug implants, today announced that screening and enrollment of the first-in-human clinical trial, known as LIBERATE-1™, has been initiated at two centers in Australia to investigate the safety, tolerability and full pharmacokinetic profile of an exenatide implant. This study is the first clinical application of the Company’s proprietary NanoPortal™ drug implant technology.
Vivani Medical launches first-in-human trial of its exenatide implant in Australia, aiming to support chronic weight management with innovative GLP-1 technology.
Vivani Medical, Inc. (NASDAQVANI) (the “Company” or “Vivani”), an innovative biopharmaceutical company developing miniaturized, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present and participate in a panel discussion at the Innovation in Obesity Therapeutics Summit West Coast, taking place in San Diego, California, from December 10-12, 2024.
Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-acting drug implants, today reported financial results for the third quarter ended September 30, 2024, and provided a business update.
Vivani Medical, Inc. (NASDAQVANI) (the “Company” or “Vivani”), an innovative biopharmaceutical company developing miniaturized, ultra long-acting drug implants, announced today that it will present at two upcoming events in October: (1) Partnership Opportunities in Drug Delivery (PODD), taking place in Boston on October 28 and 29, 2024 and (2) the ThinkEquity Conference, taking place in New York on October 30, 2024.
Vivani Medical receives approval for the first human trial of its GLP-1 obesity implant in Australia. The LIBERATE-1 trial will assess safety, tolerability, and weight loss outcomes, with data expected by 2025.
Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, biopharmaceutical company developing novel, ultra long-acting drug implants, today announced that the Bellberry Human Research Ethics Committee (“HREC”) has approved and the Therapeutic Goods Administration (“TGA”) in Australia has formally acknowledged a first in human clinical trial of the Company’s miniature, subdermal GLP-1 (exenatide) implant in obese and overweight subjects. This clinical trial, known as LIBERATE-1™, will investigate the safety, tolerability and full pharmacokinetic profile of an exenatide implant and represents the first clinical application of the Company’s proprietary NanoPortal™ drug implant technology.
Vivani Medical, Inc. (NASDAQVANI) (the “Company” or “Vivani”), an innovative biopharmaceutical company developing miniaturized, ultra long-acting drug implants, announced today that it will present at the Emerging Growth Conference on September 25, 2024.
Vivani Medical reports promising preclinical liver fat reduction results with its exenatide implant for obesity, showing potential as a differentiated treatment option. The LIBERATE-1 clinical trial is set to begin in Q4 2024.
Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative biopharmaceutical company developing miniature, ultra long-acting, subdermal drug implants, today reported positive preclinical liver fat results with its exenatide implant.
Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative biopharmaceutical company developing miniature, ultra long-acting, subdermal drug implants, today announced its plans to participate in the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11, 2024 in New York, New York.
Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-acting drug implants, today reported financial results for the second quarter ended June 30, 2024, and provided a business update.
Vivani Medical plans to start the first clinical study of the NPM-115 program in Australia in Q4 2024. The study will evaluate a 6-month GLP-1 implant for chronic weight management in obese or overweight patients. The trial includes comparisons with semaglutide and exenatide injections.
Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, biopharmaceutical company developing novel, long-term drug implants, today announced that it expects to initiate the first clinical study in the NPM-115 program in the fourth quarter of 2024 in Australia, pending regulatory clearance in that country. The NPM-115 clinical program will evaluate the investigational 6-month GLP-1 implant for chronic weight management in patients who are either obese or overweight with a related comorbidity.
Vivani Medical shares are trading higher Thursday after the company announced the FDA cleared the Investigational New Drug application and lifted the clinical hold on NPM-119.
Vivani Medical cleared FDA for NPM-119 trial in type 2 diabetes. LIBERATE-1 will assess safety, tolerability, & pharmacokinetics. NPM-115 & NPM-139 also in development for weight management.
Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, biopharmaceutical company developing novel, long-term drug implants, today announced the U.S. Food and Drug Administration has cleared the Investigational New Drug Application (“IND”) and lifted the clinical hold on NPM-119 to allow initiation of LIBERATE-1™, a Phase 1 clinical trial to assess the safety, tolerability and pharmacokinetics of NPM-119 (exenatide), the Company’s miniature, six-month GLP-1 implant in development for the treatment of type 2 diabetes.
Vivani Medical announced proof-of-concept data for a subdermal exenatide implant designed for feline obesity and diabetes, which was published in BMC Veterinary Research.
Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants including its lead asset NPM-115 for chronic weight management in obese or overweight human patients with one or more risk factors, today announced the publication of positive proof-of-concept weight loss data with OKV-119, a miniature, subdermal, exenatide drug implant designed to treat feline obesity and diabetes, in the peer-reviewed BMC Veterinary Research. The Company has licensed the rights of its exenatide delivery system, supported by the proprietary NanoPortal™ platform, to development partner, Okava Pharmaceuticals, which is studying OKV-119 for the treatment of pre-diabetes, diabetes and obesity in companion felines.
